Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

Abstract

[This corrects the article DOI: 10.3389/fphar.2023.1124214.].

Keywords: EDP; EET; cytochrome P450; hepatocellular carcinoma; lipidomics; omega-3 fatty acids; oxylipins; sorafenib.

FIGURE 2

Effects on the concentrations of (A) AA-, (B) DHA-, and (C) EPA-derived epoxy-PUFA EETs, EDPs, and EEQs; and (D) AA-derived epoxy-PUFA plus dihydroxy-PUFA, (E) DHA-derived epoxy-PUFA plus dihydroxy-PUFA, and (F) EPA-derived epoxy-PUFA plus dihydroxy-PUFA in the plasma of n = 43 patients with hepatocellular carcinoma (HCC) without and undergoing sorafenib treatment (ng/mL ± standard error of the mean). Statistical differences were determined using the Wilcoxon signed-rank test (**p < 0.01; ***p < 0.001; ****p < 0.0001).

FIGURE 3

(A) Relative n-3 (docosahexaenoic acid, DHA; eicosapentaenoic acid, EPA) and n-6 (arachidonic acid, AA) PUFA levels in plasma from n = 43 patients with hepatocellular carcinoma (HCC) without and during sorafenib treatment individually, summarized and as a ratio. (B) Relative content of saturated fatty acids (SFA), monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) in plasma from n = 43 patients with HCC without and undergoing sorafenib treatment. Statistical differences were determined using the Wilcoxon signed-rank test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

FIGURE 5

N-3 and n-6 PUFA-derived epoxides plus dihydroxy compounds as a marker for the presence of CYP metabolites in plasma from n = 43 patients with HCC without and undergoing sorafenib treatment. (A) Ratio of AA-derived products divided by AA plasma content, (B) ratio of DHA-derived products divided by DHA plasma content, (C) ratio of EPA-derived products divided by EPA plasma content (*p < 0.05, **p < 0.01; ***p < 0.001; ****p < 0.0001).